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Adjuvants enhance the immunogenicity of vaccines and improve the immune responses. Although many 
adjuvants are currently used in research, FDA approved aluminum salt (Alum) remains the most often 
used in human vaccines. Alum is known to promote the Th2 immune response and enhance antibody 
production, but is less efficient on eliciting Th1 and CTL cellular responses. Thus, it is prudent to 
improve the effectiveness of current adjuvants or to develop a novel alternative adjuvant. We have 
recently identified lunasin, a seed peptide from soybeans, as a novel immune modulator. The objective is 
to define the effectiveness of lunasin peptide as an adjuvant that can enhance the protective immunity of 
vaccines. Our studies have revealed stimulatory effects of lunasin on dendritic cells (DCs) by regulating 
expression of a number of genes that are important for immune responses.  Lunasin-treated human 
conventional DCs (cDCs) not only expressed elevated levels of co-stimulatory molecules (CD86) but also 
exhibited up-regulation of chemokines (CCL2, CCL3, CCL4) and cytokine (IL-1β). To determine the 
function of lunasin-treated cDCs, these cells were co-cultured with allogeneic human peripheral blood 
CD4+ T cells for 7 days in the mixed lymphocyte reaction. Lunasin-treated cDCs induced almost 2-fold 
higher proliferation of allogeneic CD4+ T cells when comparing with a sham treatment. To verify the in 
vivo effects, lunasin was administered into mice. Increased CD86 expression was found in cDCs from 
spleens of mice treated with lunasin. Furthermore, mice vaccinated with lunasin-adjuvanted ovalbumin 
(OVA) had reduced tumor growth following challenging with OVA-expressing A20 B-lymphoma cells. 
Taken together, our data suggest that lunasin may act as a vaccine adjuvant by targeting DCs to enhance 
and modulate the immune responses to antigens. 
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